Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faisal Mehmud

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Oncology|February 23, 2016
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell CarcinomaJose Diaz, Cora N Sternberg, Faisal Mehmud, et al.
NPJ Digital Medicine|July 16, 2019
Google searches do not correlate with melanoma incidence in majority English speaking countriesLaura McDonald, Alex Simpson, Sophie Graham, et al.
Future Cardiology|April 23, 2021
CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED risk scores and real-world oral anticoagulant prescribing decisions in atrial fibrillationMegan Besford, Thomas P Leahy, Cormac Sammon, et al.
Journal of Comparative Effectiveness Research|February 9, 2019
Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarinSreeram V Ramagopalan, Sophie Graham, Robert Carroll, et al.
Future Oncology (London, England)|October 23, 2019
Comparison of accelerometer-derived physical activity levels between individuals with and without cancer: a UK Biobank studyLaura McDonald, Mustafa Oguz, Robert Carroll, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES StudyBernard Escudier, Camillo Porta, Petri Bono, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Oncology|February 23, 2016
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell CarcinomaJose Diaz, Cora N Sternberg, Faisal Mehmud, et al.
NPJ Digital Medicine|July 16, 2019
Google searches do not correlate with melanoma incidence in majority English speaking countriesLaura McDonald, Alex Simpson, Sophie Graham, et al.
Future Cardiology|April 23, 2021
CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED risk scores and real-world oral anticoagulant prescribing decisions in atrial fibrillationMegan Besford, Thomas P Leahy, Cormac Sammon, et al.
Journal of Comparative Effectiveness Research|February 9, 2019
Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarinSreeram V Ramagopalan, Sophie Graham, Robert Carroll, et al.
Future Oncology (London, England)|October 23, 2019
Comparison of accelerometer-derived physical activity levels between individuals with and without cancer: a UK Biobank studyLaura McDonald, Mustafa Oguz, Robert Carroll, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES StudyBernard Escudier, Camillo Porta, Petri Bono, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
Pageof 2